Literature DB >> 9435526

Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo.

J Cornish1, K E Callon, D H Coy, N Y Jiang, L Xiao, G J Cooper, I R Reid.   

Abstract

Adrenomedullin is a 52-amino acid vasodilator peptide produced in many tissues, including bone. It has 20% sequence identity with amylin, a regulator of osteoblast growth, and circulates in picomolar concentrations. The present study assesses whether adrenomedullin also acts on osteoblasts. At concentrations of 10(-12) M and greater, adrenomedullin produced a dose-dependent increase in cell number and [3H]thymidine incorporation in cultures of fetal rat osteoblasts. This effect was also seen with adrenomedullin-(15-52), -(22-52), and -(27-52), but adrenomedullin-(40-52) was inactive. These effects were lost in the presence of amylin blockers, suggesting they were mediated by the amylin receptor. Adrenomedullin also increased [3H]thymidine incorporation into cultured neonatal mouse calvaria but, unlike amylin, did not reduce bone resorption in this model. Adrenomedullin stimulated phenylalanine incorporation into both isolated osteoblasts and calvaria. When injected daily for 5 days over the calvariae of adult mice, it increased indexes of bone formation two- to threefold (P < 0.0001) and increased mineralized bone area by 14% (P = 0.004). It is concluded that adrenomedullin regulates osteoblast function and that it increases bone mass in vivo. The potential of this family of peptides in the therapy of osteoporosis should be further evaluated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9435526     DOI: 10.1152/ajpendo.1997.273.6.E1113

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  An integrative genetics approach to identify candidate genes regulating BMD: combining linkage, gene expression, and association.

Authors:  Charles R Farber; Atila van Nas; Anatole Ghazalpour; Jason E Aten; Sudheer Doss; Brandon Sos; Eric E Schadt; Leslie Ingram-Drake; Richard C Davis; Steve Horvath; Desmond J Smith; Thomas A Drake; Aldons J Lusis
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

Review 2.  Current, new and future treatments of osteoporosis.

Authors:  Pooneh Salari Sharif; Mohammad Abdollahi; Bagher Larijani
Journal:  Rheumatol Int       Date:  2010-07-30       Impact factor: 2.631

3.  Research resource: Haploinsufficiency of receptor activity-modifying protein-2 (RAMP2) causes reduced fertility, hyperprolactinemia, skeletal abnormalities, and endocrine dysfunction in mice.

Authors:  Mahita Kadmiel; Kimberly Fritz-Six; Suruchi Pacharne; Gareth O Richards; Manyu Li; Tim M Skerry; Kathleen M Caron
Journal:  Mol Endocrinol       Date:  2011-05-12

Review 4.  Lactoferrin--a novel bone growth factor.

Authors:  Dorit Naot; Andrew Grey; Ian R Reid; Jillian Cornish
Journal:  Clin Med Res       Date:  2005-05

5.  SCNH2 is a novel apelinergic family member acting as a potent mitogenic and chemotactic factor for both endothelial and epithelial cells.

Authors:  Changge Fang; Ingalill Avis; Caterina Bianco; Natalie Held; Jennifer Morris; Kris Ylaya; Stephen M Hewitt; Alfred C Aplin; Roberto F Nicosia; Laura A Fung; John D Lewis; William G Stetler-Stevenson; David S Salomon; Frank Cuttitta
Journal:  Open J Clin Diagn       Date:  2013-06

6.  Amylin fasting plasma levels are decreased in patients with osteoporosis.

Authors:  J Bronský; R Průsa
Journal:  Osteoporos Int       Date:  2003-11-07       Impact factor: 4.507

7.  Glucocorticoid receptor-dependent gene regulatory networks.

Authors:  Phillip Phuc Le; Joshua R Friedman; Jonathan Schug; John E Brestelli; J Brandon Parker; Irina M Bochkis; Klaus H Kaestner
Journal:  PLoS Genet       Date:  2005-08-05       Impact factor: 5.917

8.  Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.

Authors:  Valerie A Siclari; Khalid S Mohammad; Douglas R Tompkins; Holly Davis; C Ryan McKenna; Xianghong Peng; Lisa L Wessner; Maria Niewolna; Theresa A Guise; Attaya Suvannasankha; John M Chirgwin
Journal:  Breast Cancer Res       Date:  2014-12-02       Impact factor: 6.466

9.  Poly(lactic-co-glycolic) acid/nanohydroxyapatite scaffold containing chitosan microspheres with adrenomedullin delivery for modulation activity of osteoblasts and vascular endothelial cells.

Authors:  Lin Wang; Chunyan Li; Yingxin Chen; Shujun Dong; Xuesi Chen; Yanmin Zhou
Journal:  Biomed Res Int       Date:  2013-06-11       Impact factor: 3.411

10.  Adrenomedullin delivery in microsphere-scaffold composite for remodeling of the alveolar bone following tooth extraction: an experimental study in the rat.

Authors:  Lin Wang; Ling Zheng; Chunyan Li; Shujun Dong; Lan A; Yanmin Zhou
Journal:  Biomed Eng Online       Date:  2013-10-08       Impact factor: 2.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.